INSM
Price
$137.03
Change
+$1.44 (+1.06%)
Updated
Sep 26 closing price
Capitalization
28.96B
24 days until earnings call
MDWD
Price
$17.89
Change
+$0.19 (+1.07%)
Updated
Sep 26 closing price
Capitalization
194.57M
50 days until earnings call
Interact to see
Advertisement

INSM vs MDWD

Header iconINSM vs MDWD Comparison
Open Charts INSM vs MDWDBanner chart's image
Insmed
Price$137.03
Change+$1.44 (+1.06%)
Volume$1.39M
Capitalization28.96B
MediWound
Price$17.89
Change+$0.19 (+1.07%)
Volume$52.88K
Capitalization194.57M
INSM vs MDWD Comparison Chart in %
Loading...
INSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDWD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INSM vs. MDWD commentary
Sep 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INSM is a Buy and MDWD is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 29, 2025
Stock price -- (INSM: $137.03 vs. MDWD: $17.89)
Brand notoriety: INSM and MDWD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INSM: 55% vs. MDWD: 48%
Market capitalization -- INSM: $28.96B vs. MDWD: $194.57M
INSM [@Biotechnology] is valued at $28.96B. MDWD’s [@Biotechnology] market capitalization is $194.57M. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INSM’s FA Score shows that 1 FA rating(s) are green whileMDWD’s FA Score has 1 green FA rating(s).

  • INSM’s FA Score: 1 green, 4 red.
  • MDWD’s FA Score: 1 green, 4 red.
According to our system of comparison, INSM is a better buy in the long-term than MDWD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INSM’s TA Score shows that 4 TA indicator(s) are bullish while MDWD’s TA Score has 5 bullish TA indicator(s).

  • INSM’s TA Score: 4 bullish, 4 bearish.
  • MDWD’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both INSM and MDWD are a good buy in the short-term.

Price Growth

INSM (@Biotechnology) experienced а -5.34% price change this week, while MDWD (@Biotechnology) price change was +5.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

INSM is expected to report earnings on Oct 23, 2025.

MDWD is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INSM($29B) has a higher market cap than MDWD($195M). INSM YTD gains are higher at: 98.479 vs. MDWD (0.506). MDWD has higher annual earnings (EBITDA): -30.62M vs. INSM (-938.1M). INSM has more cash in the bank: 1.86B vs. MDWD (32.4M). MDWD has less debt than INSM: MDWD (8.07M) vs INSM (576M). INSM has higher revenues than MDWD: INSM (398M) vs MDWD (19.9M).
INSMMDWDINSM / MDWD
Capitalization29B195M14,872%
EBITDA-938.1M-30.62M3,063%
Gain YTD98.4790.50619,477%
P/E RatioN/AN/A-
Revenue398M19.9M2,000%
Total Cash1.86B32.4M5,731%
Total Debt576M8.07M7,138%
FUNDAMENTALS RATINGS
INSM vs MDWD: Fundamental Ratings
INSM
MDWD
OUTLOOK RATING
1..100
8710
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
66
Overvalued
PROFIT vs RISK RATING
1..100
6100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
3953
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDWD's Valuation (66) in the Pharmaceuticals Other industry is in the same range as INSM (75) in the Biotechnology industry. This means that MDWD’s stock grew similarly to INSM’s over the last 12 months.

INSM's Profit vs Risk Rating (6) in the Biotechnology industry is significantly better than the same rating for MDWD (100) in the Pharmaceuticals Other industry. This means that INSM’s stock grew significantly faster than MDWD’s over the last 12 months.

INSM's SMR Rating (99) in the Biotechnology industry is in the same range as MDWD (99) in the Pharmaceuticals Other industry. This means that INSM’s stock grew similarly to MDWD’s over the last 12 months.

INSM's Price Growth Rating (39) in the Biotechnology industry is in the same range as MDWD (53) in the Pharmaceuticals Other industry. This means that INSM’s stock grew similarly to MDWD’s over the last 12 months.

MDWD's P/E Growth Rating (4) in the Pharmaceuticals Other industry is significantly better than the same rating for INSM (100) in the Biotechnology industry. This means that MDWD’s stock grew significantly faster than INSM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INSMMDWD
RSI
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
88%
Momentum
ODDS (%)
Bearish Trend 3 days ago
73%
Bullish Trend 3 days ago
83%
MACD
ODDS (%)
Bearish Trend 3 days ago
62%
Bullish Trend 3 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
73%
Bullish Trend 3 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
74%
Advances
ODDS (%)
Bullish Trend 6 days ago
70%
Bullish Trend 18 days ago
75%
Declines
ODDS (%)
Bearish Trend 4 days ago
75%
Bearish Trend 12 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
89%
Aroon
ODDS (%)
Bullish Trend 3 days ago
72%
Bearish Trend 3 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
INSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDWD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GHST0.04N/A
+5.96%
GHST World Inc.
ARGHF0.34N/A
+0.66%
ARGO CORPORATION
JDHIF7.93N/A
N/A
JD HEALTH INTL INC.
JUMSF27.50N/A
N/A
Jumbo SA
NCKAF0.08N/A
N/A
Nickel Asia Corporation

MDWD and

Correlation & Price change

A.I.dvisor tells us that MDWD and AKBA have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MDWD and AKBA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDWD
1D Price
Change %
MDWD100%
+1.07%
AKBA - MDWD
29%
Poorly correlated
+1.11%
BBIO - MDWD
29%
Poorly correlated
+2.14%
PRTC - MDWD
27%
Poorly correlated
-1.17%
INSM - MDWD
27%
Poorly correlated
+1.06%
VRNA - MDWD
26%
Poorly correlated
N/A
More